Akari Therapeutics, Plc announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs. Ms. Lang has more than 20 years of experience in regulatory strategy, regulatory affairs, and drug development. She will start at Akari in this role on September 1, 2023.

Before joining Akari, Ms. Lang was Senior Vice President, Regulatory Affairs and Pharmacovigilance for Enzyvant Therapeutics, where she led regulatory strategy, drug safety and operations to support therapeutics for rare diseases including congenital athymia and pulmonary arterial hypertension. Previously, she was Vice President, Regulatory Affairs for Horizon Therapeutics, leading a global regulatory organization and directing regulatory strategy ahead of the acquisition of Viela Bio and subsequent integration. Ms. Lang served as Vice President, Global Head of Regulatory Affairs at LEO Pharma A/S, where she led all aspects of global regulatory and the local support for various global locations.

She held roles of increasing scope and responsibility at Takeda Pharmaceuticals including Vice President, Global Regulatory Affairs, Marketed Products. Earlier in her career, she held various regulatory, quality, and CMC development positions at TAP Pharmaceutical Products and Abbott Laboratories. Ms. Lang received a B.S. with honors from University of Illinois at Urbana-Champaign and an M.B.A. in leadership studies from Marquette University.

She received the professional certification of US RAC from the Regulatory Affairs Professional Society.